Review Timeline | CrossMark Policy | ClinMed Features
logo
International Journal of

Cancer and Clinical ResearchISSN: 2378-3419

Archive

 Open Access DOI:10.23937/2378-3419/1410113

Treatment of Nephroblastoma in Developing Countries - Experience from a Single Center in Vietnam with NWTS 5 and SIOP 2001 Protocols

Hau Duc Tran and Ba X Hoang

Article Type: Original Research Article | First Published: April 29, 2019

We analyzed outcomes, advantages and disadvantages in application of SIOP 2001 and NWTS 5 protocols in our hospital. Patients with nephroblastoma admitted to National Children's Hospital in Hanoi, Vietnam, had been treated according to the NWTS 5 protocol from 2000-2005, and from 2008-2013 according to the SIOP 2001 protocol. 33 patients, stages I-III treated with NWTS 5 had estimated 5 year EFS 90.1% and OS 96.7% (mean follow up time 30.4 months); 58 patients, stages I-V, treated with SIOP 2001...

 Open Access DOI:10.23937/2378-3419/1410112

Common Factors among Some of the Reported Cases of the Spontaneous Remission and Regression of Cancer after Acute Infections

Behzad Niakan, Pharm D

Article Type: Hypotheses | First Published: April 25, 2019

An immunological mechanism has been suggested for the case reports of the spontaneous remission of cancer after an acute infection. The basic suggestion made is that a few acute inflammatory responses are occurring at about the same time in these cancer patients. Furthermore, it is suggested that a few acute inflammatory responses occurring at about the same time may negate the inhibitory effect of systemic inflammation on innate immunity. It is suggested that the activation of innate immunity c...

 Open Access DOI:10.23937/2378-3419/1410111

Importance of Time to Chemotherapy Initiation in Small Cell Lung Cancer

Gregory J Kubicek, Rachel Koehler, Matthew J Rossi, Christian Squillante, Alexander Hageboutros, Melvin Pratter, Stephen Akers and Polina Khrizman

Article Type: Original Article | First Published: April 20, 2019

Small cell lung cancer (SCLC) is an aggressive malignancy with a short median survival time. Because of the rapid growth rate there may be an advantage to emergently beginning chemotherapy as soon as SCLC diagnosis is made. All SCLC patients evaluated at Cooper University Hospital from January 2011 to September 2014 were reviewed. Multiple clinical factors were analyzed including timing between diagnosis and start of chemotherapy....

 Open Access DOI:10.23937/2378-3419/1410110

The Use of Carboranes in Cancer Drug Development

Emilia O Zargham, Christian A Mason and Mark W Lee Jr

Article Type: Review Article | First Published: April 18, 2019

Over the past decade, there has been a rising interest in the use of carboranes as a potential pharmacophoric moiety in the development of new drugs for the treatment of various types of cancer. The unique physical and chemical properties of carboranes make their use attractive in drug development. In several instances, the inclusion of carboranes into a drug structure has increased the agent's binding affinity, potency, or bioavailability. The purpose of this review is to highlight applications...

 Open Access DOI:10.23937/2378-3419/1410109

Does a New Information Structure about Cosmetic Outcome of Breast-Conserving Treatment Result in a Better Informed Patient? Outcome of a Comparative Case Study

ATPM Brands-Appeldoorn, MSc, AJG Maaskant-Braat, MD, PhD, VCG Tjan-Heijnen, MD, PhD and RMH Roumen, MD, PhD

Article Type: Original Article | First Published: April 17, 2019

A comparative case study compared data of two cross-sectional studies. The historical group (HG) was treated in 2013, the implementation group (IG) in 2016. The HG received a questionnaire, which resulted in implementation of the following items in our practice, expansion of the BCT brochure and photo book, incorporation of the Harvard and Numeric Rating scale. The IG received the same questionnaire, with the addition of nine more questions concerning specific implementation aspects....

 Open Access DOI:10.23937/2378-3419/1410108

Well Differentiated Neuroendocrine Uncommon Primary Breast Carcinoma: A Case Report

Angela Strazzanti, MD, Claudio Trovato, Angelo Caponnetto, Santi Gangi, Loredana R Villari, Pietro Gangemi and Francesco Basile

Article Type: Case Report | First Published: April 11, 2019

Neuroendocrine breast carcinomas (NEBC) are rarely malignant with a frequency of less than 0.1-0.3% of all breast tumors. The actual incidence of NEBC in BC (Breast Cancer) populations being still largely unknown due to the lack of a clear cut diagnostic criteria. In 2003, the World Health Organization (WHO) Classification of Tumors of the Breast and Female Genital Organs definitely established that the immunohistochemical expression of NE markers is the unique requirement for NEBC diagnosis....

Volume 6
Issue 2